COVID-19 in patients with hematologic malignancy
P Langerbeins, M Hallek - Blood, The Journal of the American …, 2022 - ashpublications.org
The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based
vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral …
vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral …
[HTML][HTML] Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Background Coronavirus disease 2019 (COVID-19) has affected> 210 million people
worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since …
worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since …
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
CM Denkinger, M Janssen, U Schäkel, J Gall, A Leo… - Nature Cancer, 2023 - nature.com
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies
CY Lee, MK Shah, D Hoyos, A Solovyov, M Douglas… - Cancer discovery, 2022 - AACR
Abstract Coronavirus disease 2019 (COVID-19) infection results in both acute mortality and
persistent and/or recurrent disease in patients with hematologic malignancies, but the …
persistent and/or recurrent disease in patients with hematologic malignancies, but the …
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
JC Enßle, J Campe, A Schwenger… - Blood, The Journal …, 2022 - ashpublications.org
Three reports address the protection of the vulnerable population of patients with
hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest …
hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest …
Immune-guided therapy of COVID-19
Vaccination has been a game changer in our efforts to address the coronavirus disease
2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for …
2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for …
SARS-CoV-2-specific T cell responses in immunocompromised individuals with cancer, HIV or solid organ transplants
DB Reeg, M Hofmann, C Neumann-Haefelin… - Pathogens, 2023 - mdpi.com
Adaptive immune responses play an important role in the clinical course of SARS-CoV-2
infection. While evaluations of the virus-specific defense often focus on the humoral …
infection. While evaluations of the virus-specific defense often focus on the humoral …
Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection
Patients with cancers have been severely affected by the COVID-19 pandemic. This is
highlighted by the adverse outcomes in cancer patients with COVID-19 as well as by the …
highlighted by the adverse outcomes in cancer patients with COVID-19 as well as by the …
CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
K Mortezaee, J Majidpoor - Frontiers in immunology, 2022 - frontiersin.org
Dysregulated innate and adaptive immunity is a sign of SARS-CoV-2-induced disease and
cancer. CD8+ T cells are important cells of the immune system. The cells belong to the …
cancer. CD8+ T cells are important cells of the immune system. The cells belong to the …